
CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
869 results found-
This of its full year results, with the in the United States which will support CSL's growing R&D appointment highlights CSL's briefing materials released to portfolio including the next-generation mRNA technology long-term commitment to the ASX on 15 August 2023.
https://www.csl.com/-/media/csl/documents/csl-governance-docs/corporate-governance-statement-2024.pdf -
On-market purchases under the plan were made twice yearly, following the announcement of CSL's half and full year results Additional shares may be purchased by NEDs on-market at prevailing share prices in accordance with CSL's Securities Dealing Policy Post-Employment Benefits Superannuation contributions are made in accordance with legislation and are included in the reported base fee, and are not additional to the base fee.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
On 17 August 2016, CSL announced its full year results for Esterase Inhibitor Subcutaneous (Human)) had been (b) of this Directors' Report.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
Shares are purchased by NEDs on-market consideration of eight Global Biopharmaceutical companies of at prevailing share prices, twice yearly, after the announcement of CSL's half and full year results.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
2025 CSL's Businesses and Outlook 16 Governance 11 February - Half Year results and interim dividend announcement Innovation Governance 56 Shares trade ex-dividend 10 March - Therapeutic Areas and 11 March - Record date for Product Portfolio 20 Directors' Report interim dividend Innovation 26 Remuneration Report 77 9 April - Interim dividend paid 30 June - Full Year ends Financial Report 19 August - Annual profit and final dividend announcement Financial Report 106 9 September - Shares trade ex-dividend Shareholder Information
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2024.pdf -
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
https://www.csl.com/ -
46 Unvested Rights represent Tranche 2 of the 2023 grant that will vest on 21 August 2023, following the release of full year financial results.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
We look forward to sharing the full results of our phase 3 study in the coming months.
https://newsroom.csl.com/2022-08-17-CSL-Announces-Positive-Top-Line-Phase-3-Results-for-Garadacimab-as-Preventive-Treatment-in-Patients-with-Hereditary-Angioedema-HAE -
CSL's Code of Responsible Business Practices guides our interactions with stakeholders and sets expectations for responsible business conduct.
https://www.csl.com/sustainability/governance/ethics-and-transparency